Black Diamond Therapeutics | SCHEDULE 13G/A:其他
Black Diamond Therapeutics | 4:持股变动声明-高管 Velleca Mark A.
Black Diamond Therapeutics | 4:持股变动声明-高管 Yurasov Sergey
Black Diamond Therapeutics | 4:持股变动声明-高管 Buck Elizabeth
Black Diamond Therapeutics | 4:持股变动声明-高管 Jones Erika
Black Diamond Therapeutics | 4:持股变动声明-高管 Hatzis-Schoch Brent
Black Diamond Therapeutics | 4:持股变动声明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股变动声明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股变动声明-董事 Campbell Shannon
Black Diamond Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-T. Rowe Price Investment Management, Inc.(19.0%)
Black Diamond Therapeutics | SC 13G:超过5%持股股东披露文件-Vestal Point Capital, LP(8.9%),Ryan Wilder(8.9%)
Black Diamond Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 10-Q:2024财年三季报
Black Diamond Therapeutics | 8-K:黑钻疗法公布2024年第三季度财务业绩并提供公司最新情况
Black Diamond Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 8-K:重大事件
Black Diamond Therapeutics | 8-K:重大事件
Black Diamond Therapeutics | 4:持股变动声明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股变动声明-董事 Campbell Shannon
Black Diamond Therapeutics | 4:持股变动声明-董事 Raman Prakash